Importance of Circulating Leptin and Adiponectin in the Causal Pathways Between Obesity and the Development of Colorectal Cancer in Japanese Men
Journal of Epidemiology · 2024
DOI: 10.2188/jea.je20230148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Epidemiology, 2024. Verfasst von Masataka Taguri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Data Science, Tokyo Medical University. Hauptthemen laut MEDLINE: Adiponectin, Colorectal Neoplasms, Leptin, Obesity. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Cancer Center Research and Development Fund, Japan Society for the Promotion of Science, Ministry of Health, Labor and Welfare of Japan.
Abstract (Originalsprache)
BACKGROUND: The mechanistic associations between obesity and risk of colorectal cancer (CRC) remain unclear. Here, using body mass index (BMI) as an obesity indicator, we decomposed the total effects of obesity on the risk of CRC into: (1) direct effects, which are possibly mediated by unmeasured or currently unknown factors; (2) indirect effects mediated by circulating leptin and adiponectin; and (3) indirect effects that are not mediated by circulating leptin and adiponectin but by hyperinsulinemia and chronic inflammation (assessed via circulating connecting peptide and C-reactive protein, respectively). METHODS: We adopted a causal mediation framework, using data from a large prospective cohort study of 44,271 Japanese men. RESULTS: BMI was not associated with the risk of CRC due to direct and indirect effects that were not mediated by circulating leptin and adiponectin. By contrast, individuals with BMIs of 25.0-27.4 kg/m2 (risk ratio 1.29; 95% confidence interval, 0.98-1.69) and ≥27.5 kg/m2 (risk ratio 1.28; 95% confidence interval, 0.98-1.68) had a higher risk of CRC due to indirect effects of circulating leptin and adiponectin. CONCLUSION: Our mediation analyses suggest that the association between BMI and CRC risk may be largely mediated by a pathway involving circulating leptin and adiponectin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Data Science, Tokyo Medical University.
- Division of Biostatistical Research, Institution for Cancer Control/Biostatistics Division, Center for Research Administration and Support, National Cancer Center.
- Graduate School of Health Innovation, Kanagawa University of Human Services.
- Division of Epidemiology, National Cancer Center Institute for Cancer Control.
- Division of Cohort Research, National Cancer Center Institute for Cancer Control.
- Department of Health Data Science, Graduate School of Data Science, Yokohama City University.
ORCID-Profile: Masataka Taguri, Aya Kuchiba, Taiki Yamaji, Norie Sawada, Atsushi Goto, Motoki Iwasaki, Shoichiro Tsugane
Förderung
- National Cancer Center Research and Development Fund
- Japan Society for the Promotion of Science
- Ministry of Health, Labor and Welfare of Japan
Zitieren
APA
Taguri, M., Kuchiba, A., Yamaji, T., Sawada, N., Goto, A., Iwasaki, M., & Tsugane, S. (2024). Importance of Circulating Leptin and Adiponectin in the Causal Pathways Between Obesity and the Development of Colorectal Cancer in Japanese Men. Journal of Epidemiology. https://doi.org/10.2188/jea.je20230148
Vancouver
Taguri M, Kuchiba A, Yamaji T, Sawada N, Goto A, Iwasaki M, et al. Importance of Circulating Leptin and Adiponectin in the Causal Pathways Between Obesity and the Development of Colorectal Cancer in Japanese Men. Journal of Epidemiology. 2024. doi:10.2188/jea.je20230148
BibTeX
@article{Taguri2024,
author = {Taguri, Masataka and Kuchiba, Aya and Yamaji, Taiki and Sawada, Norie and Goto, Atsushi and Iwasaki, Motoki and Tsugane, Shoichiro},
title = {Importance of Circulating Leptin and Adiponectin in the Causal Pathways Between Obesity and the Development of Colorectal Cancer in Japanese Men},
journal = {Journal of Epidemiology},
year = {2024},
doi = {10.2188/jea.je20230148}
}
EUVIMED